Table 2. Factors associated with virological suppression (HIV-RNA <400 copies/ml) during the first year of antiretroviral therapy.

	OR (95% CI)	aOR (95% CI)†
Female gender	1.41 (0.81–2.45)	2.06* (1.08–3.91)
Age (years)	0.98 (0.91–1.06)	0.91 (0.81–1.02)
Disadvantaged community	0.67 (0.36–1.23)	0.44 (0.14–1.40)
Living with parents	1.34 (0.74–2.41)	1.16 (0.47–2.83)
WHO clinical stage 3–4	1.40 (0.80–2.46)	1.54 (0.75–3.17)
Baseline VL>100,0000 c/ml	0.39 (0.1–1.59)	0.24 (0.02–2.49)
NRTIs
d4T+3TC	1 (reference)	1 (reference)
AZT+3TC	0.70 (0.41–1.21)	0.53 (0.27–1.03)
ABC+3TC	1.99 (0.24–16.24)	1.66 (0.17–16.08)
Use of liquid formulations	0.44* (0.24–0.81)	0.47 (0.21–1.05)
12-month AIDS risk (%)	1.00 (0.96–1.03)	1.01 (0.96–1.06)
LPVr vs. NNRTI	2.53* (1.19–5.38)	3.19* (1.11–9.13)

3TC, lamivudine; aOR, adjusted odds ratio; ABC, abacavir; AZT, zidovudine; CI, confidence interval; LPVr, lopinavir boosted with ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; VL, viral load.

*P-value<0.05;

^†To include all patients in the multivariable model, missing values of baseline viral load and 12-month AIDS risk were imputed using chained equations (64 children had complete data available).